Gan & Lee Pharmaceuticals. (SHA:603087)

China flag China · Delayed Price · Currency is CNY
75.90
-0.47 (-0.62%)
Sep 30, 2025, 3:00 PM CST
-0.62%
Market Cap45.19B
Revenue (ttm)3.80B
Net Income (ttm)919.44M
Shares Out595.42M
EPS (ttm)1.55
PE Ratio49.03
Forward PE38.92
Dividend1.50 (1.98%)
Ex-Dividend DateJun 11, 2025
Volume13,398,068
Average Volume18,927,373
Open76.20
Previous Close76.37
Day's Range75.70 - 77.09
52-Week Range40.40 - 82.25
Beta0.89
RSI55.89
Earnings DateOct 23, 2025

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; ... [Read more]

Sector Healthcare
Founded 1998
Employees 5,245
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603087
Full Company Profile

Financial Performance

In 2024, SHA:603087's revenue was 3.05 billion, an increase of 16.77% compared to the previous year's 2.61 billion. Earnings were 614.66 million, an increase of 80.75%.

Financial Statements

News

There is no news available yet.